1. United States Food and Drug Administration. FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer. [Accessed 5 June 2022].
2. Bioconjugator. Antibody-Drug Conjugate Structure.,2017
3. Ocular adverse events associated with antibody–drug conjugates in human clinical trials;Eaton;J Ocul Pharmacol Therapeut,2015
4. Therapeutic potential of tisotumab vedotin in the treatment of recurrent or metastatic cervical cancer: a short report on the emerging data;Agostinelli;Cancer Manag Res,2023
5. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study;Coleman;Lancet Oncol,2021